In the second part of this study, we proposed a possible anti-tumor strategy that involved NLRP3 inflammasome modulation using both pharmacological and molecular inhibitors followed by the classical administration of the anti-tumor agent PTX. This evidence concerns the gene NLRP3 and neoplasm.